Navigation Links
Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
Date:12/10/2008

ST. PAUL, Minn., Dec. 10 /PRNewswire/ -- Prime Therapeutics LLC (Prime) announces that it has been chosen by Blue Cross and Blue Shield of Montana (BCBSMT) to provide commercial pharmacy benefit management services, beginning January 1, 2009.

Prime will provide pharmacy benefit services to more than 175,000 BCBSMT members enrolled in health plans that include prescription drug coverage. The three-year contract covers a range of pharmacy benefit services including: claims processing, clinical programs, formulary administration, manufacturer contracting, member services, pharmacy network management, prescription mail service and specialty services. In addition, Prime will continue to provide Medicare Part D administration for BCBSMT, a service it has been providing for the health plan since 2006.

Key factors influencing the selection of Prime included the Blues-owned PBM's ability to provide supreme attention to member services and its integrated medical and pharmacy capabilities as well as its industry-unsurpassed customer satisfaction ratings. "Prime's reputation for strong customer service and pharmacy expertise were important factors in our decision," said Blue Cross and Blue Shield of Montana President and Chief Executive Officer Sherry Cladouhos. "As a Blues-owned PBM, we are relying on Prime to deliver the service-oriented, reliable programs Blue Cross and Blue Shield of Montana strives to offer in all our services."

"Prime welcomes Blue Cross and Blue Shield of Montana's business. Our operational scalability and innovative pharmacy approach positions us to efficiently add Blue Cross and Blue Shield of Montana to our growing family of Blues clients," said Tim Dickman, Prime's President and Chief Executive Officer. "The value of an integrated, in-house pharmacy continues to provide the aligned, full service solution that our Blues partners are seeking."

Prime Therapeutics is a phar
'/>"/>

SOURCE Prime Therapeutics LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
3. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
4. Prime Therapeutics Announces URAC Accreditation
5. Prime Minister views innovative health technology at Imperial College London
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. Prime Healthcare Services Acquires Centinela Hospital Medical Center
8. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
9. Announcing Prime Vendor Contract with LIHPA
10. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
11. Fetal Alcohol Exposure May Prime Offspring for Alcoholism
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 1Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 2Discovery of natural odors could help develop mosquito repellents 13710 1Discovery of natural odors could help develop mosquito repellents 13710 2Discovery of natural odors could help develop mosquito repellents 13710 3Senator Ted Kennedy 3A A Member of the NAMI Family 55466 1Senator Ted Kennedy 3A A Member of the NAMI Family 55466 2